Advertisement
News
Subscribe to MDT Magazine News

Sermo Study shows 70% of Specialists are Ready to Replace Warfarin

December 3, 2010 7:38 am | by Bio-Medicine.Org | Comments

CAMBRIDGE, Mass., Dec. 3, 2010 /- Sermo ( http://www.sermo.com ), the world's largest online community for physicians, today announced a free Sermo Report titled, " Potential Replacements for Coumadin (warfarin) ." The report gathered feedback from physicians about awareness and...

TOPICS:

Streamline Health to Announce Third Quarter Fiscal Year 2010 Financial Results on Wednesday, December 8

December 3, 2010 7:38 am | by Bio-Medicine.Org | Comments

CINCINNATI, Dec. 3, 2010 /- Streamline Health Solutions, Inc. (Nasdaq: STRM ) announced today that it will release third quarter fiscal year 2010 financial results for the period ended October 31, 2010 on Wednesday, December 8, 2010 after the market closes. The Company will conduct a...

TOPICS:

Unilife Completes A$23.1 Million Private Placement

December 3, 2010 7:38 am | by Bio-Medicine.Org | Comments

LEWISBERRY, Pa., Dec. 3, 2010 /- Unilife Corporation ( Unilife or Company ) (Nasdaq: UNIS ; ASX: UNS) announced today that it has completed the A$23.1 million private placement ( Placement ), which was previously announced on 29 November 2010. Unilife issued 27,228,143 CHESS Depositary...

TOPICS:
Advertisement

Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference

December 3, 2010 7:37 am | by Bio-Medicine.Org | Comments

MYSTIC, Conn. and DUBLIN, Dec. 3, 2010 /- Amarin Corporation plc (Nasdaq: AMRN ) today announced that it is scheduled to present at the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference on Tuesday, December 7, 2010 at 3:00pm PST. The conference will be held at...

TOPICS:

AACR Applauds Cancer Objectives in Healthy People 2020, Underscores Importance of Federal Funding for Research

December 3, 2010 7:36 am | by AACR | Comments

WASHINGTON, D.C. - The American Association for Cancer Research commends the U.S. Department of Health and Human Services (HHS) on the establishment of science-based, 10-year objectives to reduce the incidence of cancer, which was included as part of the Healthy People 2020 initiative...

TOPICS:

Summary Information for: SEDASYS? Computer-Assisted Personalized Sedation System(2)

December 3, 2010 7:32 am | Comments

Information for SEDASYS? Computer-Assisted Personalized Sedation System (P080009).

Conmed receives FDA OK for Altrus surgical system

December 3, 2010 6:45 am | by The Associated Press | Comments

Surgical equipment maker Conmed Corp. said Friday that the Food and Drug Administration has approved its Altrus thermal-energy based tissue fusion system.The Utica, N.Y., company said it expects modest revenue of between $5 million and $10 million next year for the system, but it should be a...

WellPoint says executives Fluegel, Miller to leave

December 3, 2010 4:45 am | by The Associated Press | Comments

WellPoint Inc. has announced the departure of two executives who helped explain earlier this year the health insurer's controversial rate increases for individual coverage in California.The Indianapolis insurer said Thursday evening Chief Strategy and External Affairs Officer Bradley Fluegel...

Advertisement

Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy

December 3, 2010 4:34 am | by Bio-Medicine.Org | Comments

ATLANTA, Dec. 3, 2010 /- Elekta recently received 510(k) clearance from the U.S. Food and Drug Administration for its XiO® treatment planning software to plan spot scanning. Spot scanning is a proton therapy delivery method that involves constructing a highly conformal dose to the...

TOPICS:

InfraReDx to Present at Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference

December 3, 2010 4:33 am | by Bio-Medicine.Org | Comments

BURLINGTON, Mass., Dec. 3, 2010 /- InfraReDx, Inc. , a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that James E. Muller, M.D., founder and chief executive officer, will be presenting at the 5th Annual Canaccord Genuity...

TOPICS:

CareFusion Launches Next-Generation Clinical Pulmonary and Cardiopulmonary Diagnostics Software

December 3, 2010 4:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Dec. 3, 2010 /- CareFusion (NYSE: CFN ), a leading, global medical device company, today announced the launch of SentrySuite, a new set of software applications that improve the quality of patient data and increase clinician productivity and efficiency in pulmonary and...

TOPICS:

Semicon Taiwan 3D Forum: Major players reveal current status of 3D IC commercialization

December 3, 2010 12:37 am | by I-Micronews | Comments

The Semicon Taiwan 3D Technology Forum held in Taipai in September was chaired by Ho-Ming Tong, General Manager and CTO for ASE. Speakers included representatives from UMC, ASE, SIliconware, ITRI, Yole, Nokia, Qualcomm, Verigy, Applied Materials, IME and Sematech.

Regenesance Closes Financing Round

December 3, 2010 12:36 am | by Bio-Medicine.Org | Comments

AMSTERDAM, Dec. 2, 2010 /- Regenesance BV, an Amsterdam-based specialty pharma focusing on developing drugs to treat acute and chronic nerve disorders, announces the closure of its first seed stage financing round.  The investment was made by Life Sciences Fund Amsterdam, an...

TOPICS:

A New Online Pharmacy rxbuys.com by RX Corp Offers its Services to International Clients

December 3, 2010 12:36 am | by Bio-Medicine.Org | Comments

LAS VEGAS, Dec. 3, 2010 /- It is natural that all customers using the services of online pharmacies would like to get high quality medicines, paying less for them and getting their order within the shortest possible time. That is why emergence of rxbuys.com is very timely and well-taken....

TOPICS:

Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

December 3, 2010 12:36 am | by Bio-Medicine.Org | Comments

SEATTLE, Dec. 3, 2010 /- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading